Diphtheria-tetanus-inactivated poliovirus vaccine - Sanofi
Alternative Names: REVAXIS; Td-eIPVLatest Information Update: 04 Apr 2022
Price :
$50 *
At a glance
- Originator sanofi pasteur
- Developer Sanofi
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Poliomyelitis; Tetanus
Most Recent Events
- 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
- 29 Oct 2004 Launched for Diphtheria in United Kingdom (IM)
- 29 Oct 2004 Launched for Poliomyelitis in United Kingdom (IM)